Answers are grounded in this paper and cite their sources.
Shows enhanced macromolecule delivery in HL-60 cells, suggesting redox priming via microplasma is effective.
Efficient delivery of therapeutic macromolecules into hematopoietic suspension cells remains a bottleneck for gene- and immune-therapy workflows. Here we frame a contact-free microplasma priming approach as ReMod (Redox-guided Modulation): a reversible, cytocompatible “tune-rather-than-force” strategy that gates uptake through controlled extracellular redox inputs. A 150-kDa fluorescein isothiocyanate–dextran (FD-150) was used as a model cargo in HL-60 leukemia cells. Culture-medium RONS were tuned using N 2 + 0–10% O 2 + H 2 O, Ar + 0–10% O 2 + H 2 O, and Ar + 0–10% N 2 + H 2 O, all at a total flow of 4 Lmin⁻ 1 . A brief 3-min non-thermal exposure produced a chemically tunable plasma–liquid interface and revealed a cytocompatible RONS “sweet spot” for FD-150 internalization, maximized under N 2 + 5% O 2 + H 2 O. Scavenger experiments, together with exogenous H 2 O 2 , indicated that extracellular H 2 O 2 is a principal effector of uptake. Time-integrated intracellular ROS showed a modest O 2 -dependent increase, whereas NO-related fluorescence exhibited a larger fold-increase at 1–5% O 2 , suggesting that NO signaling may act as a later, reinforcing component of the redox response. qRT-PCR profiling of endocytic markers was consistent with clathrin-mediated endocytosis and macropinocytosis as dominant uptake routes under ReMod priming. These findings define a practical redox-gating window for macromolecule delivery into suspension leukemia cells without electroporation and provide a basis for extending microplasma ReMod to nucleic-acid or immunotherapeutic payloads.
No takes yet. Share an insight, caveat, or question.
Hasan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: